Clinical trials: Elderly Lymphoma Patients
Hodgkin's Disease, Lymphoma
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
The purpose of this study is to replace a drug with many side effects, procarbazine, with a new novel drug, vorinostat, in a drug combination for the treatment of patients with diffuse large B-cell lymphoma.
- Trial name
- NCT00667615
- Testing
- rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-Cell Lymphoma (DLBCL)
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
A Single-Arm, Open-Label, Multicenter Phase II Trial of CRP Regimen (Chidamide, Rituximab, Polatuzumab Vedotin) in Treating Elderly Patients with Previously Untreated Double-Positive Diffuse Large B-Cell Lymphoma
- Trial name
- NCT07397832
- Testing
- Chidamide, Rituximab, Polatuzumab Vedotin
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer
- Trial name
- NCT07770698
- Testing
- sonrotoclax, Azacitidine, Inotuzumab ozogamicin
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Lymphoma, Refractory B-Cell Lymphoma
Study of CAR-T Therapy in Older Patients
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life.
- Conditions
- Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS
- Trial name
- NCT04300998
- Testing
- Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Low Grade Non-Hodgkin's Lymphoma, Adult
Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma
Aims of this study are to describe the variation of QoL (Quality of Life) during the clinical management of low-grade lymphoma in elderly subjects and to identify the most important factors at diagnosis and during treatment with…
- Trial name
- NCT05524298
- Where
- 21 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, CART Therapy
Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)
CAR-T cell or bispecific antibody therapies are a new treatment option for adult patients with aggressive forms of lymphoma or so-called plasma cell diseases ('multiple myeloma', 'plasma cell myeloma') that could not be cured…
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, CART Therapy, Bispecific Antibody, Geriatric Hematology
- Trial name
- GA-ACT (NCT07309497)
- Testing
- pragmatic geriatric assessment
- Where
- 2 sites in Switzerland
- Volunteers
- 208 people
- Sponsor
- University of Zurich
Lymphoma
Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00039351
- Testing
- cyclophosphamide, prednisone, vincristine sulfate
- Where
- 17 sites in Belgium, Egypt and 5 more
- Volunteers
- 32 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Diffuse Large B Cell Non-Hodgkin Lymphoma
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
Prospective, multicenter, single arm, phase II study, to evaluate the efficacy of the combination rituximab-golcadomide as a chemo free approach in a population of older patients with new diagnosis of DLBCL, defined as frail…
- Trial name
- FIL_RICCO (NCT06835530)
- Testing
- Rituximab + Golcadomide (CC-99282)
- Where
- 20 sites in Italy
- Volunteers
- 47 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Non Hodgkin Lymphoma, Follicular Lymphoma
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
This is a prospective multicenter phase II pilot trial designed with the purpose of dose finding to evaluate the efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated…
- Trial name
- REAL07 (NCT00907348)
- Testing
- LR-CHOP21
- Where
- 18 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B-Cell Lymphoma
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise…
- Trial name
- ACRUE (NCT05952024)
- Testing
- Acalabrutinib, Rituximab
- Where
- 57 sites in United States, Brazil and 3 more
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Mantle Cell Lymphoma
Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years
The purpose of the study is to better and systematically collect clinical data on the treatment of ibrutinib combined with R-CHOP/DHAP regimen for more scientific and accurate evaluation, our center has carried out the…
- Trial name
- NCT05429918
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Non-hodgkin Lymphoma,B Cell
SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
This is a multicenter prospective observational study lead by the FIL on sarcopenia and sGA as possible predictors of efficacy and toxicity outcomes in patients undergoing CAR-T cells treatment.
- Trial name
- NCT06156774
- Testing
- Chimeric Antigen Receptor T-cells (CAR-T) therapy
- Where
- 21 sites in Italy
- Volunteers
- 130 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma, Large B-cell, Diffuse
Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma
Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) combination is considered as the new gold standard for the first-line treatment of elderly patients with diffuse large B-cell lymphoma…
- Trial name
- NCT01181999
- Testing
- rituximab
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Chonnam National University Hospital
Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
The purpose of this research study is to learn about the safety of the treatment with a combination of bendamustine and rituximab and to find out what effects, both good and bad this treatment has on DLBCL.
- Conditions
- Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell, Diffuse Large-Cell Lymphoma, Lymphoma
- Trial name
- NCT01234467
- Testing
- Bendamustine, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Diffuse Large B Cell Lymphoma (DLBCL)
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) to a split-dose CHP chemotherapy backbone will improve outcomes for…
- Trial name
- NCT06594939
- Testing
- Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Medical College of Wisconsin
Lymphoma
Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with a corticosteroid, such as dexamethasone, may be an effective treatment for non-Hodgkin's lymphoma.
- Trial name
- NCT00003278
- Testing
- dexamethasone, radiation therapy
- Where
- 14 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adult Acute Lymphocytic Leukemia
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
The study evaluates the efficacy and tolerability of a dose-reduced chemotherapy for the treatment of elderly patients with acute lymphoblastic leukemia.
- Trial name
- NCT00198978
- Testing
- Cyclophosphamide, Dexamethasone / Prednisolone, Cytarabine
- Where
- Germany
- Volunteers
- 377 people
- Sponsor
- Goethe University
High Grade Lymphomas CD20 Positive
Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma
R-CHOP with doxorubicin is the standard first line treatment of high grade non-Hodgkin's lymphoma. In order to avoid central venous system insertion and reduce hospitalization time in elderly patients, we developed an oral…
- Trial name
- NCT01958996
- Testing
- idarubicin
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Poitiers University Hospital
Acute Lymphoblastic Leukemia
Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia
The main purpose of this study is to determine the maximum tolerated and efficient dose of GRASPA® in combination with polychemotherapy treatment of elderly patients with ALL, 55 years and over, Philadelphia chromosome-negative…
- Trial name
- NCT01523782
- Testing
- GRASPA
- Volunteers
- 30 people
- Sponsor
- ERYtech Pharma
Diffuse Large B-Cell Lymphoma
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
This study aims to assess the efficacy and safety of the chemotherapy-light combination of glofitamab, polatuzumab vedotin and zanubrutinib (GPZ) in elderly patients with previously untreated diffuse large B-cell lymphoma.
- Trial name
- NCT07012980
- Testing
- Glofitamab, Polatuzumab Vedotin, Zanubrutinib
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Zhongshan Hospital